Skip to content
Bora Haber
Markets
  • US dollar50.44up 0.05%
  • Euro55.34down 0.18%
  • British pound66.55down 0.11%
  • BIST 10011,477down 3.08%
  • Gold (gram)6,041down 3.55%
  • Gold (ounce)US$3,725down 3.6%
  • BitcoinUS$62,686down 1.61%
BREAKING

2027 Program Targets Support for Domestic Vaccine, Biotech Drug and Medical Device Production

The 2027 Presidential Annual Program aims to reduce import dependence in drugs and medical devices and to support vaccine and biotechnological drug production.

Nehir Gökçe

· 3 min read

A black-gloved hand picks up one of five glass vials on a red background; the central vial has a blank label.
Illustrative image: domestic vaccine and biotechnology drug production support. Temsili görsel · Fotoğraf: Thirdman / Pexels

Under the 2027 Presidential Annual Program, the leverage effect of public procurement will be used in the drug and medical device sector. The aim is to raise competitiveness in the global market, reduce import dependence and ensure supply security. Steps will be taken to develop production, R&D, clinical research, testing and analysis infrastructure.

Vaccines and biotechnological drugs

"New vaccine candidate" projects carried out through industry, public and private sector partnerships will be supported. Vaccines in the immunization program will also be made producible in Türkiye. Production and development of biosimilar drugs will be supported, and calls will be opened for priority drug technologies and biotechnological drugs. To improve access to medicines, financial and infrastructure support mechanisms will be set up, in line with patent rules, for domestic production of biotechnological drugs whose protection has recently expired or will soon expire.

Clinical research, testing and startups

Startups developing vaccines, drugs, medical devices, diagnostic kits and AI-based health technologies will receive scientific advice for clinical research. Guidance will be provided on protocols, site selection, volunteer participation, ethics committees and regulatory processes. An accelerator center model will be designed for health and biotechnology startups, and a "pilot acceleration program" will be run. Certification programs on the use of laboratory animals will be organized, and strategic cooperation with the private sector will be established for prototypes of domestic cancer diagnostic kits.

Testing, certification and licensing infrastructure with international accreditation will be created. Preparations for ISO 15189, ISO 20387 and ISO 27001 standards will be carried out for the laboratory at the Aziz Sancar Research Center.

Medical devices, exports and technology transfer

Projects transferring technology to the medical device field from other sectors, especially defense, will be supported. Innovative technology projects usable for military and civilian purposes and submitted to the TÜBİTAK Industrial R&D Support Program and SME R&D Start-up Support Program calls will get priority. Public procurement will be used effectively to help commercialize medical devices developed with public support. Methods for establishing a Health Valley will be determined and legislative work carried out. A digital supply and tracking system will be created so that drugs, devices and consumables needed by health facilities Türkiye has established or supports abroad are sourced from domestic producers. Export control units under the Turkish Medicines and Medical Devices Agency will be set up to lift drug export restrictions and implement mutual recognition agreements with the European Union.

Current state of the sector

According to data in the program, drug production rose 12.2 percent in January-July compared with the same period last year. In the first eight months of the year, 1.74 billion boxes were sold on the Turkish drug market, worth 418.4 billion liras. In the first seven months, domestically produced drugs held a 92 percent market share by volume and 52.5 percent by value. In medical devices, foreign trade volume was about $4.5 billion in 2025, with exports of $1.3 billion. The ratio of exports covering imports was 46 percent in the first five months of this year.

Science guides

Take a quiz, vote in a poll

Video news

Comments

Sign in to comment.

More on this topic

See all